Key Dates

Related Announcements

RFA-NS-23-007 -HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
RFA-NS-23-006 -HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to alert potential applicants of the National Heart, Lung, and Blood Institute's (NHLBI) specific interests and guidance in RFA-NS-23-007
"HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)".

Section I. Funding Opportunity Description in RFA-NS-23-007 has been modified, as follows:

Current NHLBI Specific Language:

B. NIH Institute and Center Interests and Guidance

NHLBI specific language not present.

Modified to Read (addition shown in bold italics):

B. NIH Institute and Center Interests and Guidance

National Heart Lung and Blood Institute (NHLBI)

The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, blood, and sleep (HLBS) diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. The NHLBI is interested in funding technologies for pain management in patients with conditions that include, but are not limited to, the following: sickle cell disease, hemophilia, deep venous thrombosis, chronic obstructive pulmonary disease, cystic fibrosis, primary ciliary dyskinesia, sarcoidosis, acute lung Injury, interstitial lung disease, angina, vasculitis, pericarditis severe chronic cough, peripheral arterial disease, and lymphedema. The NHLBI is also interested in supporting the development of pain management strategies for patients undergoing cardiac or lung transplant surgery, mechanical ventilation, tube thoracostomy, airway clearance therapy, and patient populations at risk of opioid-induced respiratory depression.

Additionally, the NHLBI is interested in supporting the development of technologies and strategies to reduce barriers to pain management of HLBS conditions in underserved and health disparity populations, culturally-sensitive pain assessment tools, evidence-based strategies to improve the implementation and adaption of pain management regimens in health disparity populations. Finally, the NHLBI is interested in the development of tools for multi-level interventions to eliminate treatment disparities among HLBS patients dealing with chronic pain.

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries regarding this Notice to:

Stephanie Meyers Davis, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Phone: 301-496-8412
E-mail: stephanie.davis3@nih.gov